Can a Person With Heart Disease Use Weight Loss Injections?

Having heart disease does not, by itself, automatically prevent the use of weight loss injections. Some people whose cardiovascular disease is under control and who have health risks associated with overweight or obesity may use weight loss injections after the type of heart disease, current symptoms and medications are evaluated. However, every person with heart disease and every weight loss injection cannot be assessed in the same way.

The use of a specific product containing semaglutide to reduce the risk of major cardiovascular events consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with established cardiovascular disease and overweight or obesity has been approved by the U.S. Food and Drug Administration. This shows that heart disease is not always a contraindication to GLP-1-based treatments. However, this approval does not mean that all weight loss injections have the same heart-protective effect or that every person with heart disease is suitable for treatment.

The decision to use a weight loss injection should be made by evaluating whether the heart disease is stable, heart rate, blood pressure, kidney function, fluid balance, diabetes status and heart medications together. This content is intended for general information and does not replace a personal medical evaluation.

Why Is the Type of Heart Disease Important?

Heart disease does not refer to a single diagnosis. Coronary artery disease, a previous heart attack, heart failure, heart valve diseases, arrhythmias, atrial fibrillation and hypertension require different forms of follow-up and treatment.

For example, a person who had a heart attack in the past and has been stable for a long time is not assessed in the same way as someone with newly developed chest pain or shortness of breath at rest. Before starting a weight loss injection, the diagnosis, current status and medications used should be known.

The following information is important during the evaluation:

• The exact diagnosis of the heart disease
• History of heart attack, stent placement or bypass surgery
• Whether heart failure is present
• The type of arrhythmia
• Resting heart rate
• Blood pressure values measured at home and in the clinic
• History of fainting or severe dizziness
• Heart and blood pressure medications
• Use of blood thinners
• Kidney function and fluid balance
• History of diabetes and low blood sugar

Can People With Coronary Artery Disease Use Weight Loss Injections?

Coronary artery disease is a cardiovascular condition associated with narrowing or blockage of the vessels that supply the heart muscle. Overweight and obesity may increase cardiovascular risk together with high blood pressure, type 2 diabetes and abnormal blood fats. Therefore, weight management may be part of the overall heart health plan in suitable individuals.

In the FDA evaluation involving adults with established cardiovascular disease and overweight or obesity, the rate of major cardiovascular events was reported as 6.5% with semaglutide treatment and 8% in the placebo group. The composite endpoint of the study included cardiovascular death, non-fatal heart attack and non-fatal stroke. These findings apply to a specific semaglutide product and a defined patient group and cannot automatically be applied to other medications.

The presence of coronary artery disease may not prevent treatment by itself. However, if there is newly developed or progressively worsening chest pain, a recent serious cardiac event, unexplained shortness of breath or symptoms at rest, the heart disease should be evaluated first.

Can Weight Loss Injections Be Used After a Heart Attack, Stent or Bypass Surgery?

For people who have previously had a heart attack, a stent or bypass surgery, the decision to use a weight loss injection should be made according to the timing and current health condition. Having experienced a heart attack in the past does not mean that the treatment can never be used.

However, the treatment plan may be more sensitive in the period immediately following a heart attack, stent procedure or bypass surgery. Reduced appetite, nausea, vomiting or rapid weight change may affect adequate nutrition, fluid balance and the medication schedule. Therefore, a weight loss injection should not be started before cardiac treatment has become stable and the medications used have been reviewed.

The following points may be assessed before treatment:

• Time since the cardiac event or surgery
• Whether chest pain is continuing
• Exercise capacity and shortness of breath
• Blood pressure and resting heart rate
• Current evaluations of heart function
• Blood thinners and other heart medications
• Kidney function
• Nutrition and fluid intake
• Cardiology follow-up plan

If chest pain, cold sweating, significant shortness of breath, fainting or rapidly worsening symptoms occur, emergency healthcare should be contacted without waiting for an online consultation.

Can People With Heart Failure Use Weight Loss Injections?

Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs. The type of disease, pumping function of the heart, fluid accumulation, kidney function and medications used may vary from person to person.

Some people with stable heart failure may be evaluated for overweight or obesity treatment. However, if there is active fluid accumulation, rapidly worsening shortness of breath, newly developed leg swelling or significant weight gain over a short period, whether heart failure is worsening should first be investigated. These symptoms may indicate fluid accumulation in the body.

Weight loss injections may cause nausea, vomiting and diarrhoea in some people. These effects may lead to fluid loss, low blood pressure and changes in kidney function. Fluid balance may need to be monitored more closely in people taking diuretics for heart failure. It is not safe for the person to excessively increase water consumption, change the diuretic dose or stop heart medications without medical guidance.

Can People With Arrhythmias Use Weight Loss Injections?

An arrhythmia is when the heart beats faster, slower or more irregularly than normal. Atrial fibrillation, tachycardia, bradycardia and other arrhythmias have different causes and risks.

Having an arrhythmia does not mean that a weight loss injection cannot be used in every situation. However, small average increases in resting heart rate may occur with some GLP-1-based medications. Current FDA product information states that an average increase of 1 to 4 beats per minute in resting heart rate was reported in adults treated with semaglutide and that heart rate should be regularly monitored. In tirzepatide studies, the average increase was reported as 1 to 3 beats per minute.

The rhythm status should be assessed before treatment, particularly in people with atrial fibrillation, frequent tachycardia attacks, unexplained fainting or a pacemaker. A physician should be informed if prolonged palpitations at rest, a racing or pounding heartbeat, dizziness or fainting develops.

Urgent evaluation is required if palpitations are accompanied by chest pain, serious shortness of breath, changes in consciousness or fainting.

Can People With High Blood Pressure Use Weight Loss Injections?

High blood pressure is an important health condition that may occur with overweight or obesity and affect cardiovascular risk. People with high blood pressure should continue their treatment plan, have regular follow-up and not change their medications without medical advice.

Controlled hypertension is not listed by itself as a contraindication in the official information for weight loss medications containing semaglutide or tirzepatide. In some adults with overweight, hypertension may even be one of the weight-related accompanying conditions that leads to the consideration of weight management medication. However, it is important to monitor blood pressure after treatment begins.

If fluid loss occurs because of nausea, vomiting or diarrhoea, blood pressure may fall more than usual. FDA data state that hypotension may occur more frequently in people using semaglutide or tirzepatide who are receiving blood pressure-lowering treatment. If dizziness when standing, darkening of vision, weakness or a feeling of faintness occurs, blood pressure should be measured and the treating physician should be informed.

What Should Be Considered When Using Heart Medications at the Same Time?

A significant proportion of people with heart disease use more than one medication. Blood pressure medications, beta blockers, diuretics, blood thinners, cholesterol medications and antiarrhythmic medications may be included in the treatment plan.

Semaglutide and tirzepatide may delay stomach emptying and affect the absorption process of some oral medications. Therefore, the effects of oral medications requiring clinical or laboratory monitoring may need to be followed more closely. This does not mean that a definite interaction will occur with every heart medication.

All medications, vitamins and supplements should be reported to the physician before treatment. The following medication groups should be assessed in particular:

• Blood pressure-lowering medications
• Beta blockers
• Diuretics
• Blood thinners
• Antiarrhythmic medications
• Cholesterol-lowering medications
• Insulin and blood sugar-lowering medications
• Oral medications that require regular laboratory monitoring

The doses of some medications may need to be reassessed over time because of weight loss, changes in eating patterns and lower blood pressure. However, no heart medication should be reduced or stopped by the person without medical guidance.

Can Weight Loss Injections Cause Heart Palpitations?

Some weight loss injections may cause an increase in resting heart rate. A brief and mild increase does not always mean that a serious arrhythmia is present. However, the duration of the palpitations, when they began and whether other symptoms accompany them are important.

Current FDA information for a weight loss medication containing semaglutide recommends monitoring heart rate at regular intervals and informing a healthcare professional if a racing heartbeat is felt at rest. If there is a persistent increase in resting heart rate, whether treatment should continue should be reassessed by a physician.

Prompt evaluation should be obtained in the following situations:

• Prolonged palpitations at rest
• A sensation of an irregular heartbeat
• Chest pain accompanying palpitations
• Shortness of breath accompanying palpitations
• Severe dizziness or fainting
• Newly developed significant weakness
• Heart rate consistently remaining above the person’s normal values

Which Checks May Be Performed Before a Weight Loss Injection in People With Heart Disease?

The same tests are not required for every person with heart disease. Checks are determined according to the type of heart disease, symptoms and medications used. The treatment decision should not be made solely on the basis of body weight or body mass index.

The following checks may be considered during an endocrinology evaluation and, when necessary, with a cardiology opinion:

• Current blood pressure and resting heart rate
• The diagnosis of heart disease and whether it is stable
• History of chest pain, shortness of breath, palpitations and fainting
• Electrocardiography or previous rhythm assessments
• Kidney function and electrolytes
• Fasting blood glucose and HbA1c
• Blood lipids
• All prescription and non-prescription medications used
• History of heart attack, stent placement, bypass surgery or hospitalisation
• Expected benefits and potential risks of weight management treatment

When prescription weight management medications are being considered, current health conditions, other medications, family history, expected benefits and potential side effects should be evaluated together.

Which People With Heart Disease Require a More Careful Evaluation?

Although the presence of heart disease does not automatically prevent use, some situations require a more detailed evaluation before treatment begins.

Situations requiring greater caution include:

• Newly developed or uncontrolled chest pain
• A recent serious cardiovascular event
• Significant shortness of breath at rest
• Rapidly increasing leg swelling
• Unexplained weight gain over a short period
• Frequent or uncontrolled arrhythmia
• Recurrent fainting
• Very low or uncontrolled high blood pressure
• A high risk of serious fluid loss
• Use of multiple blood pressure medications or high-dose diuretics
• Impaired kidney function
• Use of oral medications requiring precise dose monitoring

In these situations, the current heart disease may need to be stabilised first, followed by a reassessment of weight management options.

Which Symptoms Should Be Monitored During Treatment?

Follow-up of weight loss injections in people with heart disease should not focus only on the amount of weight lost. Heart rate, blood pressure, fluid status, kidney function and changes in heart disease symptoms should be assessed together.

The main issues that should be monitored include:

• A persistent increase in resting heart rate
• New or more frequent palpitations
• Dizziness when standing
• Blood pressure lower than usual
• Persistent vomiting or diarrhoea
• Inability to drink fluids
• Reduced urine output
• Newly developed swelling of the legs or ankles
• A significant reduction in exercise capacity
• Shortness of breath that worsens at night
• Rapid and unexplained weight changes

Vomiting, diarrhoea and inadequate fluid intake should be monitored more closely, particularly in people with heart disease who take blood pressure medications or diuretics. Dose increases should be planned by a physician according to how well the person tolerates the medication.

Which Symptoms Require Emergency Healthcare?

Some symptoms in people with heart disease should not be considered ordinary side effects of a weight loss injection. Emergency healthcare should be contacted without waiting for an online consultation in the following situations:

• Newly developed or severe chest pain
• Pressure, tightness or heaviness in the chest
• Serious or rapidly worsening shortness of breath
• Fainting or changes in consciousness
• Chest pain accompanying palpitations
• Speech disturbance, facial drooping or weakness on one side
• Cold sweating and severe weakness
• Sudden worsening of heart disease symptoms
• Very low blood pressure with serious fluid loss
• Dizziness that prevents the person from standing

Serious shortness of breath or chest pain may require emergency evaluation for an arrhythmia or coronary heart disease.

Why Is Regular Endocrinology Follow-Up Important?

Weight management in people with heart disease should be considered together with metabolic status, blood sugar, thyroid function, kidney health, blood pressure and medications used. Whether a weight loss injection is appropriate is not determined only by how much weight the person wants to lose.

During regular endocrinology follow-up, the medication dose, rate of weight loss, digestive tolerance, heart rate and blood pressure changes can be assessed. When necessary, coordination with a cardiologist can help ensure that the existing cardiac treatment and weight management plan support one another safely.

Heart medications may need to be reassessed because of weight loss or changes in blood pressure during treatment. These changes should not be made without the opinions of the relevant specialists.

Evaluate Your Weight Management Process With an Online Endocrinologist Through Happ Health

For people with heart disease, the decision to use a weight loss injection should be made by evaluating the type of heart disease, current symptoms, blood pressure, heart rate, kidney function and medications together.

Through the Happ Health digital healthcare platform, you can reach an online endocrinologist and evaluate your weight management needs, metabolic risks and weight loss injection options with a specialist opinion. During the consultation, your heart medications, previous procedures and current test results can be reviewed, and individual follow-up needs can be planned.

In emergencies such as chest pain, serious shortness of breath, fainting, changes in consciousness or signs of stroke, the nearest healthcare facility should be contacted without waiting for an online consultation.

References

• U.S. Food and Drug Administration. Wegovy semaglutide current prescribing information.
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s005lbl.pdf
• U.S. Food and Drug Administration. Zepbound tirzepatide current prescribing information.
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
• National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity.
• https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
• National Heart, Lung, and Blood Institute. Heart failure.
• https://www.nhlbi.nih.gov/health/heart-failure
• National Heart, Lung, and Blood Institute. Living with heart failure.
• https://www.nhlbi.nih.gov/health/heart-failure/living-with
• National Heart, Lung, and Blood Institute. Arrhythmias.
• https://www.nhlbi.nih.gov/health/arrhythmias
• National Heart, Lung, and Blood Institute. Arrhythmia symptoms.
• https://www.nhlbi.nih.gov/health/arrhythmias/symptoms
• National Heart, Lung, and Blood Institute. Coronary heart disease symptoms.
• https://www.nhlbi.nih.gov/health/coronary-heart-disease/symptoms
• National Heart, Lung, and Blood Institute. Living with high blood pressure.
• https://www.nhlbi.nih.gov/health/high-blood-pressure/living-with